Short Vince's Biosketch

 

 

Vincenzo Cerullo

ResearchID:B-9075-2015

ORCID: 0000-0003-4901-3796

You can contact me by email or by social media

 

Current Position

Tenure-track associate professor Faculty of Pharmacy University of Helsinki 

Head of Drug Research Program Helsinki

Group Leader ImmunoViroTherapy Lab (IVTLab) 

 

1.              EDUCATION AND DEGREE AWARDED

23/10/1998      Master of Pharmacy and Pharmaceutical Chemistry (5 years), score 110/110 cum laude University of Naples “Federico II”. Title of the Thesis: Crellastatin A: A Cytotoxic Bis-Steroid Sulfate from the Vanuatu Marine Sponge Crella sp. Supervisors: Professors Luigi Minale and Mariavaleria D’Auria

3 Jun 1999      Board of Pharmacy

17 Jun 2004    Doctor in Biotechnology, University of L’Aquila and University of Naples “Federico II”. Title of the thesis: Development of Helper-dependent Adenoviral Vectors for gene therapy of Atherosclerosis. Supervisors: Professor Lucio Pastore and Professor Fabrizio Pane.

13 May 2011   Docent (equivalent to adjunct professor or senior lecturer) of Experimental Virology, University of Helsinki.

 

2.              OTHER EDUCATION AND TRAINING, QUALIFICATIONS AND SKILLS

-       Pedagogy education at University of Helsinki (35ECTs) teaching in higher Education

-       Clinical trials development and clinical research – ASGCT

 

3.          LINGUISTIC SKILLS

Italian: mother tongue English: fluent Spanish: good Finnish: entry (second level Helsingin Aikuisopisto, training still on-going) Swedish: good (wife and children Swedish-speaking)

 

4.              CURRENT POSITION

16/09/2016      Head of Drug Research Program at Faculty of Pharmacy

01/12/2016      Tenure-track associate professor Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki

16/09/2012      Group Leader Immunovirotherapy Lab (IVTLab)

 

5.              PREVIOUS WORK EXPERIENCE and MOBILITY

  Tenure-track Associate Professor, Head of Drug Research Program 

09.16 to now

Tenure-track Assistant professor

09.12-09.16

Senior Researcher, Cancer Gene Therapy Group, University of Helsinki

2009-2012

Postdoc,  Baylor College of Medicine, Houston TX USA

2004-2008

PhD Student, CEINGE University of Naples Federico II, Italy EU

2001-2004

Exchange Student Baylor College of Medicine, Houston TX, USA

2001-2002

Master Student, Department of Chemistry of the Natural Compounds, University of Naples, Italy, Europe

1993-1998

 

 

6.              RESEARCH FUNDING, LEADERSHIP AND SUPERVISION:

MAJOR RESEARCH FUNDING GRANTS AWARDED (as PI)

100,000.00€

FP7-PEOPLE-IRG-2008 (PI) (2009-2013) (Lab expenses)

120,000.00€

University of Helsinki Postdoctoral Researcher (PI) (2010-2013)

140,000.00€

University of Helsinki Three years research grant (PI) (2013-2015) 

25,000.00€

Cancer Finnish Foundation (PI) (2014)

270,000.00€

Tekes - the Finnish Funding Agency for Innovation

80,000.00€

Finnish Cancer Foundation (PI) (2016-2017)

350,000.00€

NOVO Nordisk Seed (Pre-seed fund) (PI) (2016-2017)

2,000,000.00€

ERC-CoG grant (European Council of research) (2016-2021)

 

SUPERVISION OF YOUNG RESEARCHERS AND MENTORED PhD THESIS:

2007-2010       Candidate: Joao Dias; Thesis Title: Adenoviral gene therapy for advanced Head and Neck cancer. Approved with distinction by the faculty of Medicine

2012-2014       Candidate: Mariangela Garofalo; Title: Oncolytic Adenovirus loaded with L-carnosine as drug delivery system for cancer therapy

2011-2014       Candidate: Mari Hirvinen; Title: Immunovirotherapy of cancer – Immunological boosting and personalizing of viral cancer therapeutics 

2013-2016       Candidate: Lukasz Kuryk; Title: Development of novel immune-boosted oncolytic adenoviruses for treatment of mesothelioma

2012-presentCandidate: Cristian Capasso; Title: Personalized cancer vaccine development

2016-present Candidate: Manlio Fusciello; Title: Dendritic Cells therapy for cancer

 

7.          TEACHING COMPETENCES:

PEDAGOGICAL COMPETENCE AND TRAINING

2010-2013       University of Helsinki: Pedagogy I “Teaching and Learning in higher education” (YP1), Pedagogy II ”Design and implementation and assessment of teaching” (YP2), Pedagogy III “Academic Supervising” and Pedagogy IV “Assessment of learning”, Pedagogy V “Development of teaching and practical training” (YPV) (ongoing); (25 ECTs in total).

 

TEACHING DEVELOPMENT AT UNIVERSITY OF HELSINKI

2012, 2013, 2014 and 2015    Lecturer in the course of Biopharmaceutical II (Resp. Adyary Fallarero)

2012, 2013, 2014 and 2015    Lecturer in Adv. Biopharmaceutics (Resp. prof. Arto Urtti)

2014-to now Responsibility for the development, design, implementation and lecturing of a master level course, Advanced Immunobiology (5 credits, including theoretical and practical parts)

2017-to now Responsibility for the development, design, implementation and lecturing of a master level course, Biological Drugs II (5 credits, including theoretical and practical parts)

 

INVITED LECTURER AS SCIENTIFIC EXPERT (SELECTED FROM 30)

2008             Safety and toxicity of adenoviral vector, University of Helsinki, Faculty of Medicine, Haartman Institute, Finland

2010             Series of lectures on the use of adenovirus as vector for cancer gene. Department of Immunology University of Verona, Italy

2012             Adenovirus-gene therapy from bench to bedside, CEINGE and University of Naples, Italy

2012             Oncolytic viruses for Cancer gene therapy, University of Liverpool, United Kingdom

2013             Adenovirus-gene therapy from bench to bedside, Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy

 

8.              SCIENTIFIC AWARDS AND HONORS:

1993      Scholarship at the Pharmaceutical Chemistry Department of University of Naples

1998      “Erasmus” Scholarship at “Universitat de Barcelona” Spain

1998      University of Naples, special mention and publication of the thesis

1999      Award from Società Chimica Italiana (Italian Society of Chemist) for the Master thesis

2005      Award for presentation at Cell and Gene Therapy, Galveston TX, USA

2012      “New investigator of the month” awarded by the American Society of Cell and Gene Therapy

2013      Nominated for Outstanding New Investigator Award by American Society of Gene and cell therapy

2014      Young Investigator Award at ESGCT (European Society of Gene and Cell Therapy)

2015  Nominated for Outstanding New Investigator Award by American Society of Gene and cell therapy

 

9.          Additional Academic merits

-       Participation as Pre-examiner of Doctoral Theses (5)

-       Participation as appointed Doctoral examinations at European School of Molecular Medicine (SEMM) (4)

-       Organizing Committee for the European Society of Gene and Cell therapy meeting 2015

-       2014-on    Strategy planning group member for the Faculty of Pharmacy, University of Helsinki

----------------------------------------------------------

2012                ASGCT - Abstract Reviewer for the “Adenovirus and other DNA viruses” category

2013-2016      ASGCT – Committee Rosters “Immune response to gene and cell therapy”

2014                ASGCT - Abstract Reviewer for the “Cancer-Immunotherapy” category

2015                ASGCT - Abstract Reviewer for the “Cancer-Oncolytic Viruses” category

2015                ESGCT – Local committee organizer and member for the event in Helsinki

 

PATENTS AND INVENTIONS

1.  Title: “Antigen specific immunosuppression by dendritic cell therapy”

Patent No. : US20080311140

2.  Title: “Adenoviral vectors and methods and uses related thereto”

    Patent No. : Finnish patent office 20095466   

3.  Title: “Non-Ad5 adenoviral vectors and methods and uses related thereto”

    Patent No. : Finnish patent office 20095751

4.  Title: Ad5D24-CD40L-family, Finnish Patent pending, application #20105988

5.  Title: Ad5D24-CTLA4-family, Finnish Patent pending, application #20105991

6.  Title: VVDD-CD40L-family, Finnish patent pending, application #20115914

7.  Title: VVDD-CD40L-family, US patent pending, application #61/535429

8.  "Novel therapeutic vectors", Finnish application #20116181 and US application #61/563,634

9.  "Novel therapeutic vectors", US application #61/563,634

10.           PeptiCrad, international patent: PCT/EP2015/060903

11.           PeptiENV 4599P/GB (priority application, Great Britain).

 

10.       POSITION OF TRUST

·        Editor-in-chief of "Tumor Immunology and Immunotherapy" - Biomedicines

·        Editorial Board of Biomedicines

·        Editorial Board of Molecular Therapy Oncolytics

·        Editorial Board of the Journal of Molecular Cytotherapy

·        Editorial Board of PlosOne

·        Editorial Board of American Journal of Cancer Research and Clinical Oncology

·        Guest Editor of Biomedicines for the special issue “Gene therapy for cancer treatment”

·        Grant Reviewer for: American Institute for cancer Research (AICR), The Welcome Trust UK, and Swiss National Science Foundation

·        Board Member of the Immune Response to Gene and Cell Therapy Committee of ASGCT

·        Abstract evaluator for ASGCT 2012, 2013, 2014 and 2015 and ESGCT 2015

·        Board member of the European Society of Gene and Cell Therapy

·        Evaluator for the Italian professorship; selected from 1700 applicants by ANVUR (2013)

 

 

11.       MEMBERSHIPS OF SCIENTIFIC SOCIETIES

Finnish Society of Gene Therapy, American Society of Gene and Cell Therapy, European Society of Gene and Cell Therapy, Society for Immunotherapy of Cancer (SITC)

 

12.       MAJOR ONGOING COLLABORATIONS

International: Dotti Giampietro (Texas Children Hospital), Masataka Suzuki (Center for Gene and Cell Therapy (CGCT) Houston TX), Brendan Lee (Baylor College of Medicine, Houston TX), Luigi Buonaguro (Ospedale Pascale, Napoles, Italy), Gennaro Piccialli (Naples, Italy), Davide Melisi (Verona, Italy)

National: Akseli Hemminki, Markku Varjosalo and Dario Greco (Universty of Helsinki), Ari Hinkkanen (University of Eastern Finland).